Synergistic Cancer Treatment System

A comprehensive system integrating anti-MICA antigen binding fragments with AI, IoT, blockchain, and new materials to revolutionize cancer treatment

The original patent disclosed anti-MICA antigen binding fragments for cancer treatment. However, it lacked a comprehensive system to optimize treatment regimens, ensure secure tracking, and provide personalized therapy. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system

The synergistic system comprises a bi-specific T-cell engager, an artificial intelligence module for optimizing treatment regimens, a blockchain-based system for secure tracking, a composite material for cancer immunotherapy, and an IoT device for monitoring efficacy. The bi-specific T-cell engager is a fusion protein with two different single-chain variable fragments (scFvs), one binding to MICA or MICB and the other to an immune cell target. The AI module analyzes patient genomic data to identify specific MICA or MICB epitopes associated with the patient's cancer. The blockchain-based system ensures compliance with regulatory requirements, while the composite material provides a biodegradable polymer matrix for dispersing the bi-specific T-cell engager. The IoT device monitors the efficacy of the bi-specific T-cell engager, detecting the presence of MICA or MICB on cancer cells

The new claims introduce a synergistic combination of anti-MICA antigen binding fragments with AI, IoT, blockchain, and new materials, which is not obvious from the original patent. The integration of these distinct technologies creates a more powerful system that provides a novel approach to cancer treatment

Alternative embodiments may include using different AI algorithms, blockchain platforms, or composite materials. Variations may also include integrating additional technologies, such as CRISPR gene editing, to further enhance the system's capabilities

The synergistic cancer treatment system has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in personalized cancer treatment, cancer immunotherapy, and precision medicine